查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1599330

生物製造的重要蛋白质市场：按类别、功能和适应症分类 - 2025-2030 年全球预测

Vital Proteins for Biomanufacturing Market by Groups (Cytokines, Enzymes & Chemicals, Expression Systems), Function (Diagnostics, Drug Discovery & Development), Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

生物製造重要蛋白质市场规模2023年为521亿美元，预计2024年将达到565.2亿美元，复合年增长率为8.92%，到2030年将达到948.1亿美元。

生物製造中的关键蛋白质是治疗性蛋白质、酵素和其他生化产品生产和开发的重要组成部分。其范围包括製药、生物技术和治疗製造中的应用，促进细胞培养、蛋白质精製以及单株抗体、疫苗和重组蛋白生产所必需的配方等过程。对这些蛋白质的需求是因为它们能够提高生物基产品的效率、产量和质量，并且它们在现代生物技术过程中发挥重要作用。最终用途产业主要包括专注于药物开发和生命科学研究的製药公司、研究机构和生物技术公司。该市场的推动因素包括生技药品需求的增加、蛋白质工程的进步以及生物技术研发投资的迅速增加。永续和高效的生物工艺的日益普及凸显了商机，特别是在个人化医疗和再生疗法方面。公司可以透过专注于提高生物过程效率的创新蛋白质解决方案来利用这些机会。然而，市场面临生产成本高、监管障碍和蛋白质製造复杂性等挑战，可能会阻碍成长。蛋白质生产的可扩展性有限和技术困难也是主要障碍。业务成长的创新领域包括开发具有成本效益的蛋白质生产技术、改进蛋白质稳定和保存方法以及在新兴生物技术中为重要蛋白质创造新用途。此外，与学术和研究机构的伙伴关係促进共同创新并提供竞争优势。该市场的特点是技术快速进步，注重永续性和效率，代表着一个具有巨大成长潜力的动态环境。公司可以透过投资研究和利用最尖端科技来满足生物製造领域不断变化的需求，从而保持竞争力。

主要市场统计
基准年[2023] 521亿美元
预测年份 [2024] 565.2亿美元
预测年份 [2030] 948.1亿美元
复合年增长率（%） 8.92%

市场动态：快速发展的生物製造重要蛋白质市场的关键市场洞察

供需的动态交互作用正在改变生物製造的重要蛋白质市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 对具有增强治疗功效的生物製药的需求不断增加
    • 快速采用新型细胞培养平台来生产复杂的生物製药
    • 由于对个人化医疗的兴趣日益浓厚，对客製化蛋白质疗法的需求
  • 市场限制因素
    • 建立最先进的生物製造设施的高资本支出
  • 市场机会
    • 政府支持政策促进研发投入
    • 学术界和工业界持续合作以实现重要的蛋白质创新
  • 市场挑战
    • 与扩大生产流程相关的复杂性

波特五力：驾驭生物製造重要蛋白质市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解生物製造重要蛋白质市场的外部影响

外部宏观环境因素在塑造生物製造重要蛋白质市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解生物製造重要蛋白质市场的竞争状况

对生物製造重要蛋白质市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵生物製造重要蛋白质市场供应商的绩效评估

FPNV 定位矩阵是评估生物製造重要蛋白质市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了生物製造重要蛋白质市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对生物製造的重要蛋白质市场进行策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 对具有增强治疗功效的生物製药的需求不断增加
      • 快速部署新的细胞培养平台来生产复杂的生物製药
      • 对个人化医疗日益增长的兴趣需要客製化的蛋白质疗法
    • 抑制因素
      • 建立最先进的生物製造设施需要大量资本支出
    • 机会
      • 政府支持政策促进研发投入
      • 学术界和工业界持续合作以实现重要的蛋白质创新
    • 任务
      • 与扩大生产流程相关的复杂性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章生物製造市场的重要蛋白质（以群体划分）

  • 细胞激素
    • 趋化素
    • 集落刺激因子
    • 干扰素
    • 白细胞介素
    • 肿瘤坏死因子
  • 酵素和化学品
    • DNA加帽酶
    • 核酸内切酶
    • 糖苷酶
    • 聚腺苷酸化酶
    • 蛋白酶抑制剂
    • 转录酶
  • 表达系统
    • 细菌
    • 昆虫
    • 哺乳动物细胞
    • 酵母菌
  • 媒体和补充品
    • 白蛋白
    • 表皮生长因子（EGF）
    • 纤维母细胞生长因子（FGF）
    • 胰岛素样生长因子 (IGF)
    • 转铁蛋白
    • 血管内皮生长因子（VEGF）
  • 蛋白A树脂
  • 品管试剂
  • 载体和转染试剂

第七章生物製造的重要蛋白质市场：依功能

  • 诊断
  • 药物发现与开发
    • 生物製药
    • 细胞/基因治疗
    • 疫苗

第八章生物製造市场的重要蛋白质（按适应症）

  • 自体免疫疾病
  • 感染疾病
  • 肿瘤学
  • 罕见遗传疾病

第九章美洲生物製造重要蛋白质市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太生物製造重要蛋白质市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲/中东/非洲生物製造重要蛋白质市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • New England Biolabs 推出了 Faustovirus Capping Enzyme，这是一种用于 mRNA 生产的新型酶促 mRNA 封端解决方案。
    • Everest Medicines 获得类 3C 蛋白酶抑制剂的权利，用于开发针对 COVID-19 的抗病毒药物
  • 战略分析和建议

公司名单

  • Abcam PLC
  • Abnova Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioLegend, Inc. by PerkinElmer, Inc.
  • Biologics International Corporation
  • BPS Bioscience, Inc.
  • Bristol-Myers Squibb Company
  • Creative BioMart Inc.
  • Croyez Bioscience Co., Ltd.
  • Eli Lilly and Company
  • Enzo Life Sciences, Inc.
  • GenScript Biotech Corporation
  • Johnson & Johnson Services, Inc.
  • Laurus Bio Private Limited
  • LenioBio GmbH
  • Lonza Group AG
  • Merck KGaA
  • Meridian Bioscience, Inc. by SD Biosensor Inc.
  • Miltenyi Biotec BV & Co. KG
  • Novartis AG
  • ProMab Biotechnologies, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-D47730F51F28

The Vital Proteins for Biomanufacturing Market was valued at USD 52.10 billion in 2023, expected to reach USD 56.52 billion in 2024, and is projected to grow at a CAGR of 8.92%, to USD 94.81 billion by 2030.

Vital proteins in biomanufacturing serve as essential components in the production and development of therapeutic proteins, enzymes, and other biochemical products. Their scope includes applications in pharmaceuticals, biotechnology, and therapeutic manufacturing, where they facilitate processes like cell culture, protein purification, and formulation, crucial for producing monoclonal antibodies, vaccines, and recombinant proteins. The necessity of these proteins stems from their ability to enhance efficiency, yield, and quality of bio-based products, underscoring their indispensable role in modern biotechnological processes. End-use sectors primarily include pharmaceutical companies, research institutes, and biotech firms focusing on drug development and life sciences research. The market is driven by key factors such as increased demand for biologic drugs, advancements in protein engineering, and a surge in investment in biotechnological research and development. The growing adoption of sustainable and efficient bioprocesses highlights opportunities, particularly in personalized medicine and regenerative therapies. Companies can leverage these opportunities by focusing on innovative protein solutions that enhance bioprocess efficiency. However, the market faces challenges like high production costs, regulatory barriers, and the complexity of protein manufacturing, which can impede growth. Limited scalability and technical difficulties in protein production also present significant hurdles. For business growth, areas of innovation include developing cost-effective protein production technologies, improving methods of protein stabilization and storage, and creating novel applications for vital proteins in emerging biotechnologies. Additionally, partnerships with academic and research institutions can spur collaborative innovation, offering competitive advantages. The market is characterized by rapid technological advancements and a strong emphasis on sustainability and efficiency, indicating a dynamic environment with significant potential for growth. Companies can stay competitive by investing in research and harnessing cutting-edge technologies to meet the evolving demands of the biomanufacturing sector.

KEY MARKET STATISTICS
Base Year [2023] USD 52.10 billion
Estimated Year [2024] USD 56.52 billion
Forecast Year [2030] USD 94.81 billion
CAGR (%) 8.92%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vital Proteins for Biomanufacturing Market

The Vital Proteins for Biomanufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing demand for biopharmaceuticals with enhanced therapeutic efficacy
    • Rapid adoption of novel cell culture platforms to produce complex biotherapeutics
    • Growing interest in personalized medicine necessitates tailored protein therapeutics
  • Market Restraints
    • High capital expenditure requirements for establishing state-of-the-art biomanufacturing facilities
  • Market Opportunities
    • Supportive government policies promoting investments in research & development
    • Ongoing collaborations between academia & industry players for technological innovations in vital proteins
  • Market Challenges
    • Complexities associated with scaling up production processes

Porter's Five Forces: A Strategic Tool for Navigating the Vital Proteins for Biomanufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vital Proteins for Biomanufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vital Proteins for Biomanufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vital Proteins for Biomanufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vital Proteins for Biomanufacturing Market

A detailed market share analysis in the Vital Proteins for Biomanufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vital Proteins for Biomanufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vital Proteins for Biomanufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vital Proteins for Biomanufacturing Market

A strategic analysis of the Vital Proteins for Biomanufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vital Proteins for Biomanufacturing Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Abnova Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., BioLegend, Inc. by PerkinElmer, Inc., Biologics International Corporation, BPS Bioscience, Inc., Bristol-Myers Squibb Company, Creative BioMart Inc., Croyez Bioscience Co., Ltd., Eli Lilly and Company, Enzo Life Sciences, Inc., GenScript Biotech Corporation, Johnson & Johnson Services, Inc., Laurus Bio Private Limited, LenioBio GmbH, Lonza Group AG, Merck KGaA, Meridian Bioscience, Inc. by SD Biosensor Inc., Miltenyi Biotec B.V. & Co. KG, Novartis AG, ProMab Biotechnologies, Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Vital Proteins for Biomanufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Groups, market is studied across Cytokines, Enzymes & Chemicals, Expression Systems, Media & Supplements, Protein A Resins, Quality Control Reagents, and Vectors & Transfection Reagents. The Cytokines is further studied across Chemokines, Colony-stimulating factors, Interferons, Interleukins, and Tumor necrosis factors. The Enzymes & Chemicals is further studied across DNA Capping Enzymes, Endonucleases, Glycosidases, Polyadenylation Enzymes, Protease Inhibitors, and Transcription Enzymes. The Expression Systems is further studied across Bacterial, Insect, Mammalian Cells, and Yeast. The Media & Supplements is further studied across Albumin, Epidermal Growth Factor (EGF), Fibroblast Growth Factors (FGFs), Insulin-like Growth Factors (IGFs), Transferrin, and Vascular Endothelial Growth Factor (VEGF).
  • Based on Function, market is studied across Diagnostics and Drug Discovery & Development. The Drug Discovery & Development is further studied across Biologics, Cell & Gene Therapy, and Vaccines.
  • Based on Indication, market is studied across Autoimmune Disorders, Infectious Diseases, Oncology, and Rare Genetic Disorders.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing demand for biopharmaceuticals with enhanced therapeutic efficacy
      • 5.1.1.2. Rapid adoption of novel cell culture platforms to produce complex biotherapeutics
      • 5.1.1.3. Growing interest in personalized medicine necessitates tailored protein therapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. High capital expenditure requirements for establishing state-of-the-art biomanufacturing facilities
    • 5.1.3. Opportunities
      • 5.1.3.1. Supportive government policies promoting investments in research & development
      • 5.1.3.2. Ongoing collaborations between academia & industry players for technological innovations in vital proteins
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities associated with scaling up production processes
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vital Proteins for Biomanufacturing Market, by Groups

  • 6.1. Introduction
  • 6.2. Cytokines
    • 6.2.1. Chemokines
    • 6.2.2. Colony-stimulating factors
    • 6.2.3. Interferons
    • 6.2.4. Interleukins
    • 6.2.5. Tumor necrosis factors
  • 6.3. Enzymes & Chemicals
    • 6.3.1. DNA Capping Enzymes
    • 6.3.2. Endonucleases
    • 6.3.3. Glycosidases
    • 6.3.4. Polyadenylation Enzymes
    • 6.3.5. Protease Inhibitors
    • 6.3.6. Transcription Enzymes
  • 6.4. Expression Systems
    • 6.4.1. Bacterial
    • 6.4.2. Insect
    • 6.4.3. Mammalian Cells
    • 6.4.4. Yeast
  • 6.5. Media & Supplements
    • 6.5.1. Albumin
    • 6.5.2. Epidermal Growth Factor (EGF)
    • 6.5.3. Fibroblast Growth Factors (FGFs)
    • 6.5.4. Insulin-like Growth Factors (IGFs)
    • 6.5.5. Transferrin
    • 6.5.6. Vascular Endothelial Growth Factor (VEGF)
  • 6.6. Protein A Resins
  • 6.7. Quality Control Reagents
  • 6.8. Vectors & Transfection Reagents

7. Vital Proteins for Biomanufacturing Market, by Function

  • 7.1. Introduction
  • 7.2. Diagnostics
  • 7.3. Drug Discovery & Development
    • 7.3.1. Biologics
    • 7.3.2. Cell & Gene Therapy
    • 7.3.3. Vaccines

8. Vital Proteins for Biomanufacturing Market, by Indication

  • 8.1. Introduction
  • 8.2. Autoimmune Disorders
  • 8.3. Infectious Diseases
  • 8.4. Oncology
  • 8.5. Rare Genetic Disorders

9. Americas Vital Proteins for Biomanufacturing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Vital Proteins for Biomanufacturing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Vital Proteins for Biomanufacturing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. New England Biolabs Introduces Faustovirus Capping Enzyme, a Novel Enzymatic mRNA Capping Solution for mRNA Manufacturing
    • 12.3.2. Everest Medicines Ltd. acquires rights to 3C-like protease inhibitors to develop antivirals for COVID-19
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abcam PLC
  • 2. Abnova Corporation
  • 3. Agilent Technologies, Inc.
  • 4. Bio-Rad Laboratories, Inc.
  • 5. BioLegend, Inc. by PerkinElmer, Inc.
  • 6. Biologics International Corporation
  • 7. BPS Bioscience, Inc.
  • 8. Bristol-Myers Squibb Company
  • 9. Creative BioMart Inc.
  • 10. Croyez Bioscience Co., Ltd.
  • 11. Eli Lilly and Company
  • 12. Enzo Life Sciences, Inc.
  • 13. GenScript Biotech Corporation
  • 14. Johnson & Johnson Services, Inc.
  • 15. Laurus Bio Private Limited
  • 16. LenioBio GmbH
  • 17. Lonza Group AG
  • 18. Merck KGaA
  • 19. Meridian Bioscience, Inc. by SD Biosensor Inc.
  • 20. Miltenyi Biotec B.V. & Co. KG
  • 21. Novartis AG
  • 22. ProMab Biotechnologies, Inc.
  • 23. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. VITAL PROTEINS FOR BIOMANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. VITAL PROTEINS FOR BIOMANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VITAL PROTEINS FOR BIOMANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHEMOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COLONY-STIMULATING FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INTERLEUKINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TUMOR NECROSIS FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DNA CAPPING ENZYMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENDONUCLEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GLYCOSIDASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY POLYADENYLATION ENZYMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TRANSCRIPTION ENZYMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INSECT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MAMMALIAN CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY YEAST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EPIDERMAL GROWTH FACTOR (EGF), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FIBROBLAST GROWTH FACTORS (FGFS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INSULIN-LIKE GROWTH FACTORS (IGFS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TRANSFERRIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN A RESINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY QUALITY CONTROL REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VECTORS & TRANSFECTION REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RARE GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SINGAPORE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH KOREA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. TAIWAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 184. TAIWAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 185. TAIWAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. THAILAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 192. THAILAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 193. THAILAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 194. THAILAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 199. VIETNAM VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 200. VIETNAM VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 201. VIETNAM VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 202. VIETNAM VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 203. VIETNAM VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 216. DENMARK VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 217. DENMARK VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 218. DENMARK VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 219. DENMARK VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 220. DENMARK VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 221. DENMARK VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 222. DENMARK VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. EGYPT VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 225. EGYPT VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 226. EGYPT VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 227. EGYPT VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 228. EGYPT VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 229. EGYPT VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 230. EGYPT VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 231. EGYPT VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. FINLAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 233. FINLAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 234. FINLAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 235. FINLAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 236. FINLAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 237. FINLAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 238. FINLAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 239. FINLAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. FRANCE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 241. FRANCE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 242. FRANCE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 243. FRANCE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 244. FRANCE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 245. FRANCE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 246. FRANCE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 247. FRANCE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 248. GERMANY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 249. GERMANY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 250. GERMANY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 251. GERMANY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 252. GERMANY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 253. GERMANY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 254. GERMANY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 255. GERMANY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 256. ISRAEL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 257. ISRAEL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 258. ISRAEL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 259. ISRAEL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 260. ISRAEL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 261. ISRAEL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 262. ISRAEL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 263. ISRAEL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 264. ITALY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 265. ITALY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 266. ITALY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 267. ITALY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 268. ITALY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 269. ITALY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 270. ITALY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 271. ITALY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 272. NETHERLANDS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 274. NETHERLANDS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 275. NETHERLANDS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 276. NETHERLANDS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 278. NETHERLANDS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 279. NETHERLANDS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 280. NIGERIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 281. NIGERIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 282. NIGERIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 283. NIGERIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 284. NIGERIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 285. NIGERIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 286. NIGERIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 287. NIGERIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 288. NORWAY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 289. NORWAY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 290. NORW